It further stated that the board, on the recommendation of Nomination and Remuneration Committee, has appointed Anil Raghavan as chief exec...

Some of their biggest personal investments have been in power and real estate, and both sectors and their holdings have taken a beating, ac...

ETon May 3 reported that the committee was set to reject the offer from Lakshadweep, a venture promoted by some relatives of pharma billion...

The decision to abandon plans to set up a payments bank was taken as the promoters felt that they lacked adequate physical presence in term...

Under the open offer, Shanghvi and associates had to acquire 26 per cent stake for Rs 2,837 crore in the wind turbine maker.

Telenor India will continue to position itself as the 'sabse sastaa' or the lowest costing voice and data services provider in the country.

The deal, announced in February this year, would see Shanghvi acquiring at least 23 per cent stake in Suzlon which has been grappling with ...

Troubled shipbuilder ABG Shipyard is looking for a white knight and it's now pinning hopes on India's richest man Dlilip Shanghvi for a bai...

Suzlon Energy last week signed definitive agreements with Dilip Shanghvi Family and Associates (DSA) for equity investments of Rs 1,800 cro...

This weekend, Shanghvi announced a Rs 1,400-crore investment to pick up 23% stake in ailing renewable energy company Suzlon through DSA.

Suzlon today surged nearly 20 per cent, following pacts with Dilip Shanghvi Family and Associates for equity investments of Rs 1,800 crore.

The open offer price for 157.64 crore shares is Rs 18 per scrip, a total of about Rs 2,837.52 crore.

The company plans to build wind-power equipment factories as it seeks to recover from India’s biggest convertible-bond default two-and-a-ha...

Suzlon’s promoters will retain management control “by virtue of pooling arrangement for voting”, while the Shanghvi family will remain a fi...

His staff call him India's most aggressive promoter whose calm demeanour shadows his killer instincts when it comes to splurging on riskies...

The revised guidance takes into account the risks associated with increase in competition for some products. Guidance is at constant exchan...

Pharmaceutical companies, who are battling growing competition from each other and resurgent multinationals, may have to shake hands.